SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain

NKTR-181, a new molecular entity, mu-opioid receptor agonist with an inherently slow rate of central nervous system (CNS) entry, was designed to provide analgesia while reducing abuse potential. This phase 3, enriched-enrollment, randomized-withdrawal trial evaluated the analgesic efficacy, safety,...

Descripción completa

Detalles Bibliográficos
Autores principales: Markman, John, Gudin, Jeffrey, Rauck, Richard, Argoff, Charles, Rowbotham, Michael, Agaiby, Eva, Gimbel, Joseph, Katz, Nathaniel, Doberstein, Stephen K., Tagliaferri, Mary, Lu, Lin, Siddhanti, Suresh, Hale, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553961/
https://www.ncbi.nlm.nih.gov/pubmed/30747908
http://dx.doi.org/10.1097/j.pain.0000000000001517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553961/
https://www.ncbi.nlm.nih.gov/pubmed/30747908
http://dx.doi.org/10.1097/j.pain.0000000000001517

Ejemplares similares